Summit Therapeutics SMMT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$1.21B-401% | -$1.08B-388% | -$921.62M-369% | -$746.08M-361% | -$240.76M-108% | ||
| $165K+89.7% | $146K+64.0% | $126K+29.9% | $104K-4.6% | $87K-35.6% | ||
| $794.12M+1,411% | $732.42M+1,337% | $631.66M+1,197% | $520.27M+1,631% | $52.57M+152% | ||
| -$384.05M-122% | -$322.93M-127% | -$269.67M-139% | -$206.88M-112% | -$173.14M-84.7% | ||
| $480K-13.8% | $657K+373% | $507K+299% | $494K+305% | $557K+605% | ||
| -$334.66M— | -$174.31M— | —— | —— | —— | ||
| $613.65M+48.9% | $617.53M+52.5% | $43.71M-89.4% | $214.04M+3.3% | $412.03M+5,815% | ||
| —— | —— | —— | $269.44M+542% | $150.23M+364% | ||
| -$384.53M-121% | -$323.59M-127% | -$270.17M-139% | -$207.38M-112% | -$173.7M-85.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Summit Therapeutics generate?
- Summit Therapeutics (SMMT) generated -$384.1M in operating cash flow over the trailing twelve months.
- What is Summit Therapeutics's free cash flow?
- After $480.0K of capital expenditures, Summit Therapeutics's free cash flow was -$384.5M over the trailing twelve months, down 121.4% year over year.
- Where does Summit Therapeutics's cash flow data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.